Table 1. Correlation of relative lncRNA XIST expression with the clinicopathological characteristics of patients with prostate cancer.
LncRNA XIST expression* | |||||
---|---|---|---|---|---|
Parameters | Group | High | Low | Total | P value |
Age | <70 | 18 | 9 | 27 | 0.324 |
≥70 | 19 | 16 | 35 | ||
Metastasis | Absence | 26 | 7 | 33 | <0.01 |
Presence | 11 | 18 | 29 | ||
Clinical stage | T1 | 20 | 5 | 25 | 0.012 |
T2/T3 | 18 | 19 | 37 | ||
Preoperative PSA | <4 | 14 | 4 | 18 | 0.044 |
4-10 | 6 | 7 | 13 | ||
>10 | 13 | 18 | 31 | ||
Gleason score | <7 | 17 | 5 | 22 | 0.019 |
7 | 4 | 6 | 10 | ||
>7 | 12 | 18 | 30 |
*The mean (2.2) of the relative expression of lncRNA XIST in tumor tissues of all paired samples was used as a cut-off to classify a tumor sample was high or low according to their XIST expression levels.